Anthropic CEO Dario Amodei said the AI industry must “actually” cure cancer and deliver tangible scientific breakthroughs to win back public trust, warning that advertising and marketing alone cannot repair the deep institutional distrust now surrounding artificial intelligence.
In a lengthy post on X published Saturday, Amodei conceded that AI companies “haven’t yet delivered on our big promises to benefit the world” and called for a centralized regulator modeled on the Financial Industry Regulatory Authority (FINRA) to oversee frontier AI development.
A Trust Crisis Years in the Making
Amodei framed the industry’s core problem as a compounding distrust of both technology firms and government. He argued that the public perceives AI companies as constantly seeking “a new way to screw them over,” and that no amount of messaging can substitute for proof that the technology genuinely improves lives.
“The thing that will work is actually curing cancer,” Amodei wrote, pointing to Anthropic’s AI for Science program and what he described as “early glimmers” of biology breakthroughs as the only credible path to rebuilding confidence.
Endorsing a Central AI Regulator
The FINRA-style proposal would create a single body with authority to set and enforce safety standards across frontier AI labs, similar to how FINRA oversees broker-dealers in the United States. Amodei has been one of the most vocal advocates for AI regulation in Silicon Valley, frequently clashing with industry counterparts and policymakers over the pace and shape of oversight.
The proposal comes at a sensitive moment. Both Anthropic and rival OpenAI have confidentially filed IPO paperwork, with investors watching closely as the two most valuable private AI companies race toward public listings. Anthropic tripled its annual revenue run rate to $30 billion, surpassing OpenAI’s roughly $24 billion.
“I get really angry when someone’s like, ‘This guy’s a doomer. He wants to slow things down,'” Amodei told Business Insider in a recent interview. “My father died because of cures that could have happened a few years earlier. I understand the benefit of this technology.”
OpenAI’s Angel Brodin pushed back on Amodei’s framing in a reply, noting that the pharmaceutical industry routinely delivers advancements in public health yet “still one of the least trusted industries.” The exchange highlights a growing divide within the AI industry over whether scientific breakthroughs alone can shift public opinion, or whether structural regulatory reform is also necessary.
Amodei’s comments arrive alongside broader regulatory uncertainty. The UK government has signaled it may move toward mandatory AI regulation if voluntary safeguards prove insufficient, while the United States recently concluded its voluntary safety testing program with no new federal rules in sight.
Sources: Fortune; Business Insider; AI Weekly; Reuters
discussion